Comparison of hydroxychloroquine with methotrexate in the treatment of patients with localized scleroderma

Tabriz University of Medical Sciences and Health Services0 个研究点目标入组 30 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•presence of morphea without any signs of systemic involvement, evidence of active and expanding lesions (evidence of the spreading lesions, the appearance of new lesions or clinical signs of inflammation include erythema and warmth over the past 3 months), morphea confirmed with a histological samples from all patients before treatment, any systemic treatment with effect on morphea had to be discontinued for at least 4 weeks and topical treatments for at least 2 weeks prior to the study,
•Exclusion criteria: Acute or chronic infection, pregnancy or childbearing potential without an acceptable method to prevent, Liver disease or elevated liver enzyme levels more than twice the normal, creatinine level of more than 130 mmol, known pulmonary disease, leukocyte count less than 3500 or platelet count less than 150000, active peptic ulcer or neoplasm, insulin-dependent diabetes mellitus, Use of other anti-folate drugs such as sulfonamides, and allopurinol and Probenesid, Presence of Lupus or Mixed connective tissue disease (MCTD), Contraindication of Ophthalmology to start hydroxychloroquine

发起方

Tabriz University of Medical Sciences and Health Services